ClinicalTrials.gg
CompletedNCT00237198Updated Feb 23, 2017

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

A Phase 2 interventional study of Letrozole in Postmenopausal Women With Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 24 sites in Japan. Open to female participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
20 Years to 79 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
104th of 159
47 · median 95
Started
2004
with 8 others
Phase 2
72 of 162
13 open now
Registered
18th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 104th largest by enrollment of the 159 interventional ones that give a count, is one of 9 that started in 2004, is one of 72 in phase 2, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 20 Years to 79 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

  • Safety and efficacy of letrozole 2.5 mg/day monotherapy as second-line endocrine therapy in postmenopausal patients with advanced breast cancer who received previous anti-estrogen treatment
  • To investigate changes in blood drug concentrations and blood hormone kinetics.
  • To investigate gene polymorphisms of CYP2A6, an enzyme involved in the metabolism of letrozole
03

Conditions studied

  • Postmenopausal Women With Advanced Breast Cancer

Browse trials for

Keywords

  • Aromatase inhibitor
  • letrozole
  • breast cancer
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or cytologically documented breast cancer
  • Patients with progressive breast cancer (advanced breast cancer, locoregional recurrence not operative, or breast cancer)
  • Patients with hormone receptor (ER and/or PgR) positive or both unknown.
  • patients between ages 20 and 79 years, inclusive
  • Patients with a history of therapy or advanced breast cancer treated with anti-estrogens
  • Patients with documented measurable or evaluable lesions.
  • Patients with sufficient organ function to evaluate the safety
  • Patients whose performance status (PS) is 0~2

Exclusion criteria

Exclusion Criteria:

  • Patients with diffuse lymphangitis carcinomatosa of the lung or CNS involvement, liver occupying more than one third of the liver, or inflammatory breast cancer
  • Patients with other concurrent or previous malignant disease (excluding contralateral breast cancer, in situ carcinoma of cervix uteri, and adequately treated basal or squamous cell carcinoma of the skin)
  • Patients in whom one of the following is the sole manifestation of disease: hilar enlargement, pleural effusion and ascites
  • Patients with only blastic bone metastases or a mixed blastic and lytic bone metastases at the same site and no other measurable or evaluable lesions
  • Patients with serious current disease such as uncontrolled cardiac diseases and/or uncontrolled diabetes mellitus by any medications (including a historical serious cardiac disease)
  • Patients with adrenal insufficiency (treated or untreated) or Cushing's syndrome
  • Patients with any of the following previous treatments

    1. Chemotherapy for metastatic and/or locoregional recurrent disease
    2. Previous endocrine therapy other than ovariectomy, anti-estrogen treatment, LH-RH analogues or radiation castration
    3. Previous endocrine therapy (e.g., aromatase inhibitors and gastagens) for the treatment of metastatic and/or locoregional recurrent breast cancer other than anti-estrogen or LH-RH analogues treatment
    4. Patients who have not recovered from toxicity caused by previous therapy
    5. For patients on drugs, adequate of at least 7 days in the case of topical investigational drugs and at least 30 days in the case of systemic
    6. Previous bisphosphonate therapy started within 6 months without any other measurable or evaluable lesions
    7. Patients who have not stopped treatment with other anti-estrogen or anti-cancer drugs (other than bisphosphonates) before starting the trial medication

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Letrozole

    Drug: Letrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Safety during treatment

    Time frame: Until disease progression or appearance of unacceptable toxicity whichever comes first

  2. Response Rate during treatment

    Time frame: Until disease progression or appearance of unacceptable toxicity whichever comes first

Secondary outcomes

  1. Clinical Benefit Rate during treatment

    Time frame: Until disease progression or appearance of unacceptable toxicity whichever comes first

  2. Duration of response

    Time frame: from the first date of response confirmed and the last date of response confirmed

  3. Time to progression

    Time frame: from the first date of response confirmed and the last date of response confirmed

  4. Time to treatment failure

    Time frame: from the date of study initiation and the date of disease progression confirmed or discontinuation other than disease progression

  5. Plasma drug concentration from baseline, every 4 weeks until 28 weeks, at 40 weeks and at 52 weeks

    Time frame: Baseline, 52 weeks

  6. Plasma estrogens level

    Time frame: baseline, 52 weeks

07

Study locations

24 sites
  • Novartis Investigative Site
    Nagoya, Aichi 464-8681, Japan
  • Novartis Investigative Site
    Nagoya, Aichi 465-0024, Japan
  • Novartis Investigative Site
    Kashiwa, Chiba 277-8577, Japan
  • Novartis Investigative Site
    Matsuyama, Ehime 791-0280, Japan
  • Novartis Investigative Site
    Kooriyama, Fukushima 963-8501, Japan
  • Novartis Investigative Site
    Maebashi, Gunma 371-8511, Japan
  • Novartis Investigative Site
    Kure, Hiroshima 737-0023, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 003-0804, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 060-0001, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 063-0812, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 241-0815, Japan
  • Novartis Investigative Site
    Kurashiki, Okayama 701-0192, Japan
  • Novartis Investigative Site
    Kitaadachi-gun, Saitama 338-8553, Japan
  • Novartis Investigative Site
    Sunto-gun, Shizuoka 411-8777, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8677, Japan
  • Novartis Investigative Site
    Chuo-ku, Tokyo 104-0045, Japan
  • Novartis Investigative Site
    Cyuo-ku, Tokyo 104-8560, Japan
  • Novartis Investigative Site
    Koto, Tokyo 135-8550, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Novartis Investigative Site
    Fukuoka, 811-1395, Japan
  • Novartis Investigative Site
    Fukushima, 960-1295, Japan
  • Novartis Investigative Site
    Niigata, 951-8566, Japan
  • Novartis Investigative Site
    Osaka, 537-8511, Japan
  • Novartis Investigative Site
    Shizuoka, 420-0881, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004 and a primary completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2005
First posted
Oct 12, 2005
Start
Mar 2004
Primary completionActual
Jul 2006
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00237198
Responsible party
Sponsor
First posted
Oct 12, 2005
Start date
Mar 2004
Primary completion
Jul 2006
Last update
Feb 23, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion